NCT04513119

Unknown

The Short-term Efficacy of Novel NTDP-RFA in the Treatment o...

Southwest Hospital, China Source

Compare

Other study identifiers

Sponsor study identifier

cstc2019jscx-msxmX0230

Study Type

observational

Estimated enrollment

100

Locations

1 country

Sites

2

Timeline

Study Start

January 1, 2017

Actual (reported)

Primary Completion

July 1, 2022

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

August 31, 2022

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

To evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 100 participants
Study completion date: August 31, 2022
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 1, 2017
Actual (reported)
First Submitted
July 31, 2020
Actual (reported)
First Posted
August 14, 2020
Actual (reported)
Primary Completion
July 1, 2022
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 31, 2022
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: August 14, 2020
Status Verified: August 2020
Last Update Submitted: August 11, 2020

Conditions

Hepatocellular Carcinoma Stage I Radiofrequency Ablation

Outcome Measures

Primary Outcomes (1)

The incidence of local tumor progression (LTP)
LTP was defined as the appearance of new tumor foci near 2 cm at the ablative margin after the local eradication of all tumor cells with RFA
two-years local tumor progression-free survival

Secondary Outcomes (1)

Tumor-free survival
two-years tumor-free survival

Eligibility Criteria

Age18 Years - 70 Years

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with primary hepatocellular carcinoma with cirrhosis

You may qualify if:

Primary hepatocellular carcinoma with a background of cirrhosis

Sponsors & Collaborators

Southwest Hospital, China
Otherlead

Study Sites (2)

Institute of hepatobiliary surgery,Southwest Hospital

Chongqing, Chongqing Municipality, 400038, China

ENROLLING_BY_INVITATION

Institute of hepatobiliary surgery,Southwest Hospital

Chongqing, Chongqing Municipality, 400038, China

RECRUITING

Kai Feng, M.DCONTACT+86-23-13228683383 fengkai7688@hotmail.com

Kai Feng, M.DPRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Kuansheng Ma, Ph.D
Institute of hepatobiliary surgery,Southwest Hospital
STUDY DIRECTOR

Central Study Contacts

Kai Feng, M.D

CONTACT

+86-23-13228683383 fengkai7688@hotmail.com

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: associate professor

Study Record Dates

First Submitted

July 31, 2020

First Posted

August 14, 2020

Study Start

January 1, 2017

Actual (reported)

Primary Completion

July 1, 2022

Estimated (date passed)

NCT05991856

Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma

Recruiting

NCT05719948

Combined Continuous and Pulsed Radiofrequency Ablation for Pain Relief and Their Safety in Cervical Facet Pain

Not ApplicableCompleted

NCT04150744

RFA Plus Carrizumab vs Carrizumab Alone for HCC

Phase 2Recruiting

NCT04803890

"No-Touch" Radiofrequency Ablation for Small Hepatocellular Carcinoma (≤ 3cm): A Prospective Multicenter Study

Not ApplicableTerminated

NCT03067493

RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial

Phase 2Unknown

NCT05078541

Radiofrequency Ablation for Warthin's Tumor

Not ApplicableCompleted

Single shot with diameter ≤ 3cm

The tumor did not invade portal vein, hepatic vein trunk and secondary branches

Child Pugh A/B

ICG-R15 ≤ 30%

years old

The follow-up time reached 2 years

You may not qualify if:

The follow-up time is less than 2 years
multiple lesions or diameter \> 3cm
Previous history of upper gastrointestinal bleeding or severe hypersplenism
Patients with extrahepatic or lymph node metastasis
Wish to receive liver transplantation and hepatectomy
The lesion is adjacent to the gallbladder, important blood vessels and bile ducts in the hilum of the liver and important organs around
severe bleeding tendency, platelet count \< 50 × 10\^9/L, or prothrombin time prolonged \> 3s
Other anti-tumor therapies were accepted before surgery

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

August 31, 2022

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

August 14, 2020

Record last verified: 2020-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT04513119
Data provider: ClinicalTrials.gov
Source updated: 2020-08-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:33:02 UTC

Locations

CN(2)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations